1. Choi NK, Park BJ. Adverse drug reaction surveillance system in Korea. J Prev Med Public Health 2007;40:278–284.
2. Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA 1995;274:29–34.
3. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279:1200–1205.
4. Pearson TF, Pittman DG, Longley JM, Grapes ZT, Vigliotti DJ, Mullis SR. Factors associated with preventable adverse drug reactions. Am J Hosp Pharm 1994;51:2268–2272.
5. Onder G, Pedone C, Landi F, et al. Adverse drug reactions as cause of hospital admissions: results from the Italian Group of Pharmacoepidemiology in the Elderly (GIFA). J Am Geriatr Soc 2002;50:1962–1968.
6. Caamaño F, Pedone C, Zuccalà G, Carbonin P. Socio-demographic factors related to the prevalence of adverse drug reaction at hospital admission in an elderly population. Arch Gerontol Geriatr 2005;40:45–52.
7. Corsonello A, Pedone C, Corica F, Mussi C, Carbonin P, Antonelli Incalzi R; Gruppo Italiano di Farmacovigilanza nell'Anziano (GIFA) Investigators. Concealed renal insufficiency and adverse drug reactions in elderly hospitalized patients. Arch Intern Med 2005;165:790–795.
8. Kim MY, Yang MS, Kang HR, Cho SH, Min KU. analysis of drugs causing severe cutaneous adverse reactions, based on the Korean database of spontaneously reported adverse drug reactions. Korean J Med 2014;86:710–721.
9. Kim MG, Kang HR, Kim JH, et al. Analysis of adverse drug reactions collected by an electronic reporting system in a single hospital. Korean J Med 2009;77:601–609.
10. Avorn J. Medication use and the elderly: current status and opportunities. Health Aff (Millwood) 1995;14:276–286.
11. Atkin PA, Veitch PC, Veitch EM, Ogle SJ. The epidemiology of serious adverse drug reactions among the elderly. Drugs Aging 1999;14:141–152.
12. Brody EM. Long-term care of older people: a practical guide. 1st ed. Oxford: Human Sciences Press, 1977.
13. Rønning M, Blix HS, Harbø BT, Strøm H. Different versions of the anatomical therapeutic chemical classification system and the defined daily dose--are drug utilisation data comparable? Eur J Clin Pharmacol 2000;56:723–727.
14. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000;356:1255–1259.
15. Tantikul C, Dhana N, Jongjarearnprasert K, Visitsunthorn N, Vichyanond P, Jirapongsananuruk O. The utility of the World Health Organization-The Uppsala Monitoring Centre (WHO-UMC) system for the assessment of adverse drug reactions in hospitalized children. Asian Pac J Allergy Immunol 2008;26:77–82.
16. Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 2001;10:483–486.
17. Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm 1992;49:2229–2232.
19. Kim JE, Kyun JO, Jin SM, et al. adverse drug reactions in elderly inpatients: comparison with younger patients. Korean J Asthma Allergy Clin Immunol 2010;30:216–221.
20. Sikdar KC, Dowden J, Alaghehbandan R, MacDonald D, Peter P, Gadag V. Adverse drug reactions in elderly hospitalized patients: a 12-year population-based retrospective cohort study. Ann Pharmacother 2012;46:960–971.
21. Ciorciaro C, Hartmann K, Kuhn M. Differences in the relative incidence of adverse drug reactions in relation to age? An evaluation of the spontaneous reporting system of SANZ (Swiss Drug Monitoring Center). Schweiz Med Wochenschr 1998;128:254–258.
23. Bottiger LE. Adverse drug reaction: an analysis of 310 consecutive reports to the Swedish drug reaction committee. J Clin Pharmacol 1973;13:373–382.
24. Montastruc JL, Lapeyre-Mestre M, Bagheri H, Fooladi A. Gender differences in adverse drug reactions: analysis of spontaneous reports to a Regional Pharmacovigilance Centre in France. Fundam Clin Pharmacol 2002;16:343–346.